company background image
AUROPHARMA logo

Aurobindo Pharma NSEI:AUROPHARMA Stock Report

Last Price

₹1.34k

Market Cap

₹779.8b

7D

-2.2%

1Y

71.2%

Updated

22 Jul, 2024

Data

Company Financials +

Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹779.8b

AUROPHARMA Stock Overview

Engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally.

AUROPHARMA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends3/6

Aurobindo Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aurobindo Pharma
Historical stock prices
Current Share Price₹1,344.55
52 Week High₹1,409.90
52 Week Low₹771.00
Beta0.55
11 Month Change8.34%
3 Month Change22.99%
1 Year Change71.21%
33 Year Change41.12%
5 Year Change143.95%
Change since IPO1,908.44%

Recent News & Updates

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Recent updates

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Apr 14
Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50

Feb 11
Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Jan 08
Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Shareholder Returns

AUROPHARMAIN PharmaceuticalsIN Market
7D-2.2%-0.9%-1.3%
1Y71.2%46.4%43.1%

Return vs Industry: AUROPHARMA exceeded the Indian Pharmaceuticals industry which returned 46.4% over the past year.

Return vs Market: AUROPHARMA exceeded the Indian Market which returned 43.1% over the past year.

Price Volatility

Is AUROPHARMA's price volatile compared to industry and market?
AUROPHARMA volatility
AUROPHARMA Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.2%

Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months.

Volatility Over Time: AUROPHARMA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198623,451Kambam Reddywww.aurobindo.com

Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries.

Aurobindo Pharma Limited Fundamentals Summary

How do Aurobindo Pharma's earnings and revenue compare to its market cap?
AUROPHARMA fundamental statistics
Market cap₹779.77b
Earnings (TTM)₹31.73b
Revenue (TTM)₹290.02b

24.8x

P/E Ratio

2.7x

P/S Ratio

Is AUROPHARMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AUROPHARMA income statement (TTM)
Revenue₹290.02b
Cost of Revenue₹126.03b
Gross Profit₹163.99b
Other Expenses₹132.26b
Earnings₹31.73b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)54.15
Gross Margin56.54%
Net Profit Margin10.94%
Debt/Equity Ratio21.2%

How did AUROPHARMA perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

10%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.